Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Stem cells
- Therapeutic
- Vaccine
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 291191
(a)
the United States and foreign patents and/or patent applications listed;
(b)
United States and foreign patents issued from the applications listed and from divisionals, continuations and continuations-in-part of these applications;
(c)
claims of U.S. and foreign continuation-in-part applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed; and
(d)
claims of all foreign patent applications, and of the resulting patents, which are directed to subject matter specifically described in the United States patents and/or patent applications described in (a), (b) or (c) above.
6,087,350 – Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
6,559,139 – Combination chemotherapy
Licensed Product shall mean Vitamin D and one or more cytotoxic agents administered or otherwise used or offered for use in a manner which would, but for the license granted herein, infringe one or more of the Patent Rights.
Vitamin D shall mean cholecalciferol, as well as all derivatives and analogs thereof or thereto.
IPSCIO Record ID: 308739
Application #11/231,618 – Peptide Analogs capable of enhancing stimulation of a glioma-specific CTL response.
Patent Rights shall mean University intellectual property described below and assigned to University
(a) The United States and foreign patents and/or patent applications listed;
(b) United States and foreign patents issued from the applications listed and from divisionals, substitutions, continuations and continuation-in-parts of these applications;
(c) United States and foreign patents issued from any of the foregoing, including all reissues, registrations, renewals, reexaminations and extensions thereof; and
(d) Claims of U.S. and foreign continuation and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed.
Licensee is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
IPSCIO Record ID: 27630
For University’s Patent Rights I, II, III & IV
University hereby grants to Licensee an exclusive license along with the right to use related Technology and know-how, to develop, have developed, make, have made, market, import, sell, and otherwise use Licensed Products and to practice the licensed methods under University’s Patent Rights I, University’s Patent Rights II, University’s Patent Rights III and University’s Patent Rights IV.
For University's Patent Rights V
University hereby grants to Licensee an option to obtain a license hereunder to each individual compound that is claimed in or covered by University’s Patent Rights V, which license shall be an exclusive license in the Territory and in the Licensed field of Use, including the right to grant sub-licenses, along with the right to use related University Collective Patent Rights, Technology and Know-How, to develop, have developed, make, have made, market, import, sell, and otherwise use related Licensed Products and to practice the related licensed methods for a specified individual compound that is claimed in or covered by University’s Patent Rights V. The Option shall be exercisable on a compound-by-compound basis by written notice given within six-months of the day Licensee receives notification and enabling disclosure from University in accordance with the due-diligence requirements in this Agreement, of each new compound definable by University’s Patent Rights V. Upon exercise of any Option in accordance with the provisions, such compound and related University Patent Rights V, Technology and Know-How shall be licensed to Licensee hereunder as provided above for the consideration set forth herein.
University’s Patent Rights I or University Patent Rights I shall mean patent rights to any subject matter claimed in or covered by any of the following
Under University Case No. 224
U.S. Patent No. 4,996,237 entitled Combretastatin A-4.
Under University Case No. 700
U.S. Patent No. 5,561,122 entitled Combretastatin A-4 Prodrug and any corresponding extensions or foreign applications or patents, if any.
University’s Patent Rights II or University Patent Rights II shall mean patent rights to any subject matter claimed in or covered by any of the following
Under University Case No. 98-014
PCT Patent Application Serial No. US99/00419, entitled Synthesis of Combretastatin A-4 Prodrugs and Trans-isomers Thereof and any corresponding extensions or foreign applications or patents.
University’s Patent Rights III or University Patent Rights III shall mean patent rights to any subject matter claimed in or covered by any of the following
Under University Case No. 206
U.S. Patent Nos. 5,409,953 & 5,569,786, entitled Isolation, Structural Elucidation and Synthesis of Novel Antineoplastic Substances Denominated Combretastatins.
Under University Case No. 516
U.S. Patent No. 4,940,726, entitled Cell Growth Inhibitory Macrocyclic
Lactones Denominated Combretastatin D-1 and Combretastatin D-2 and any corresponding extensions or foreign applications or patents.
University’s Patent Rights IV or University Patent Rights IV shall mean patent rights to any subject matter claimed in or covered by continuing applications deriving from University Patent Rights I or University Patent Rights II or University Patent Rights III including all additions, renewals, divisions, substitutions, continuations and continuation-in-part applications; any patents issuing on said applications or continuing applications including reissues; and any corresponding extensions or foreign applications or patents. For the purposes of this agreement, this definition shall include only patent rights deriving from research conducted using funding from either University internal funds, philanthropic funds or funds from the United States Government. Inventions which are made exclusively under funding from third party for-profit entities or Agencies are excluded. Also excluded are inventions that are made under funding from third party for-profit entities or Agencies in combination with funding sources other than the United States Government.
University’s Patent Rights V or University Patent Rights V shall mean patent rights to any subject matter directed at any compound or group of compounds which are Combretastatins as defined herein and that is not claimed in or covered by University Patent Rights I, University Patent Rights II, University Patent Rights III or University Patent Rights IV. For the purposes of this agreement, this definition shall include only patent rights deriving from research conducted using funding from either Licensee or University internal funds, philanthropic funds or funds from the United States Government. Inventions which are made exclusively under funding from third party for-profit entities or Arizona State Agencies are excluded. Also excluded are inventions that are made under funding from third party for-profit entities or Agencies in combination with funding sources other than the United States Government.
IPSCIO Record ID: 263763
Licensor grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable, license in the Territory under such issued letters patent for Licensee to develop, make, have made, use, sell, offer for sale or import Compounds and Products in the Territory.
For the Covenants/Companion Diagnostic, Licensor grants a non-exclusive license, with the right to grant sublicenses, under Licensor Patent Rights, Licensor Know-How, and Companion Diagnostic Trademarks to market and promote the Companion Diagnostic in the Field in the Territory for use in connection with the Product and use the Companion Diagnostic in any way necessary or reasonably useful in order for Licensee to exercise the license granted by Licensor.
This agreement is to develop and commercialize a novel investigational therapeutic candidate vintafolide (EC145).
Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine monohydrazide (DAVLBH).
Etarfolatide is a folate-targeted molecular imaging agent that is being developed as a noninvasive method to identify tumors that over-express folate receptors.
Product(s) means any pharmaceutical or biological preparation.
Vintafolide is designed to preferentially target the chemotherapy agent to fast growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian, NSCLC, breast, colon and kidney.
